Clinical Trials
4 trialsNCT02411656 2026-01-23
Pembrolizumab in Treating Patients With Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT02734979 2022-10-27
Biobridge
Stanford University
Phase NA Completed
NCT00088166 2014-08-13
XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors
Celtic Pharma Development Services
Phase 3 Completed
NCT00226655 2012-08-31
An Open-Labeled, Extended-Use of XERECEPT (hCRF) for Patients in Studies NTI 0302, 0303, or Other Designated Studies
Celtic Pharma Development Services
Phase 3 Completed